Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results

Key Takeaways Cytokinetics' aficamten beat metoprolol on all key efficacy measures in phase III MAPLE-HCM study.Aficamten improved exercise capacity, symptoms, and LVOT gradients in patients with obstructive HCM.FDA review of aficamten is underway with a target decision date now set for Dec. 26, 2025.Cytokinetics, Incorporated's ((CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten.On Aug. 30, Cytokinetics presented primary results fr ...